Suven Life share price plunges 19% after Alzheimer molecule disappoints in Phase 2

Published: 2/12/2019
Suven Life share price plunges 19% after Alzheimer molecule disappoints in Phase 2
Source: WWW.MONEYCONTROL.COM

The triple therapy of Masupirdine (SUVN-502) with Donepezil and Memantine proof of concept phase 2 study missed its pre-specified primary endpoint.

Read more
Related news
Comment
Latest in blog
FACEBOOK